The Effect of Amantadine As Add-on Therapy for Motor Fluctuations in Advanced Parkinson's Disease: a Randomized Double-blinded Placebo-controlled Trial

Motor fluctuations are identified as the most challenging symptoms by parkinson disease patients. A recent post-hoc analysis of ADS-5012 trials (new formulation of ER Amantadine), revealed a significant improvement in OFF-time. No randomized clinical trial has ever specifically investigated to date the effect of amantadine IR on motor fluctuations. The main objective of this study is to evaluate the effect of amantadine (300 mg/day) as add-on therapy for the treatment of motor fluctuations (Off-time) in advanced Parkinson's disease patients versus placebo after 3 months of treatment.

开始日期2025-05-01

申办/合作机构

Toulouse University Hospital

NCT06234462

/ Recruiting临床2期IIT

Feasibility Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid: A Pilot Randomized Control Trial

Purpose: To decrease symptom burden, improve cognitive function, improve endurance, and decrease fatigue in subjects with post-acute sequelae of COVID-19 (PASC) or "long-hauler" COVID using amantadine. If amantadine use is determined to be efficacious in this population, the findings of this study will be used towards a subsequent randomized control trial.

开始日期2025-03-31

申办/合作机构

The University of Texas Southwestern Medical Center

NCT06253923

/ Recruiting临床2期

Multicenter, Double-blind, Randomized, Placebo Controlled, Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301), in Patients with Severe Traumatic Brain Injury (TBI).

The main goal of this clinical trial is to check if the treatment is safe and well-tolerated. Researchers will compare the MR-301 active drug group with the placebo group to evaluate the safety and tolerability of the drug. Other measurements include assessing the patient's overall outcome, neurological responses, time spent in the intensive care unit, time in the hospital, and mortality. Participants will receive either MR-301 BID IV dosing or a matching placebo for a total of 3 weeks.

开始日期2024-06-01

申办/合作机构

SHINKEI Therapeutics LLC初创企业

[+1]

100 项与盐酸金刚烷胺相关的临床结果

登录后查看更多信息

100 项与盐酸金刚烷胺相关的转化医学

登录后查看更多信息

100 项与盐酸金刚烷胺相关的专利（医药）

登录后查看更多信息

9,913

项与盐酸金刚烷胺相关的文献（医药）

2025-05-01·FOOD CHEMISTRY

Comprehensive multiomics analysis reveals the effects of French fries and chicken breast meat on the oxidative degradation of lipids in soybean oil during deep-frying

Article

作者: Hu, Qian ; Zhang, Ting ; Xing, Ranran ; Huang, Wensheng ; Chen, Ying ; Zhang, Jiukai

This study investigated the oxidative degradation of lipids in soybean oil used for frying French fries (SOFFF) and chicken breast meat (SOFCBM) using integrated volatolomics and oxidative lipidomics. Water in the food matrix promotes triglyceride hydrolysis. The rate of lipid hydrolysis was higher in SOFCBM, whereas the rate of lipid oxidation was higher in SOFFF. Prolonged frying with SOFFF may be more harmful to health because of the toxic oxidized triglycerides. Nitrogenous volatile derivatives are characteristic of SOFCBM. The volatile derivatives produced by SOFFF were similar to those produced by thermal processing. Ten non-volatile derivatives were identified as potential markers related to the total polar compound content, and 17 non-volatile derivatives were identified as potential markers related to deep-frying time in both SOFFF and SOFCBM. These results provide a comprehensive insight into the effects of fried foods on the oxidative degradation of lipids.

2025-04-01·TETRAHEDRON

Synthesis and functionalization of 2-iodoimidazo[1,2-a]pyridines in palladium-catalysed amino-, aryloxy- and alkoxycarbonylations

作者: Kollar, Laszlo ; Jenei, Laura Barbara ; Benyei, Attila ; Szuroczki, Peter ; Sandor, Viktor

Imidazo[1,2-a]pyridines possessing carboxamido and ester functionalities in 2- and 6-positions were synthesized in palladium-catalyzed amino- and alkoxy/aryloxycarbonylation using a great variety of amines and alcs./phenols as N- and O-nucleophiles, resp.The corresponding iodoheteroaroms., used as substrates, were synthesized from the substituted 2-aminopyridines, terminal alkynes and iodine in copper-catalyzed oxidative ring-closureiodination reaction sequence.Mono- and dinuclear copper-2-aminopyridine complexes, used as pre-formed catalysts, were characterised by X-ray crystallog.The amides and esters were obtained in moderate to high yields mainly depending on the nucleophile and not on the structure of the 2-iodo[1,2-a]pyridine substrates.

2025-03-18·ACCOUNTS OF CHEMICAL RESEARCH

Solid-State NMR of Virus Membrane Proteins

Article

作者: Hong, Mei

ConspectusEnveloped viruses encode ion-conducting pores that permeabilize the host cell membranes and mediate the budding of new viruses. These viroporins are some of the essential membrane proteins of viruses, and have high sequence conservation, making them important targets of antiviral drugs. High-resolution structures of viroporins are challenging to determine by X-ray crystallography and cryoelectron microscopy, because these proteins are small, hydrophobic, and prone to induce membrane curvature. Solid-state NMR (ssNMR) spectroscopy is an ideal method for elucidating the structure, dynamics, and mechanism of action of viroporins in phospholipid membranes. This Account describes our investigations of influenza M2 proteins and the SARS-CoV-2 E protein using solid-state NMR.M2 proteins form acid-activated tetrameric proton channels that initiate influenza uncoating in the cell. ¹⁵N and ¹³C exchange NMR revealed that M2 shuttles protons into the virion using a crucial histidine, whose imidazole nitrogens pick up and release protons on the microsecond time scale at acidic pH. This proton exchange is synchronized with and facilitated by imidazole reorientation, which is observed in NMR spectra. Quantitative ¹⁵N NMR spectra yielded the populations of neutral and cationic histidines as a function of pH, giving four proton dissociation constants (pK_a's). The pK_a's of influenza AM2 indicate that the +3 charged channel has the highest time-averaged single-channel conductance; thus the third protonation event defines channel activation. In comparison, influenza BM2 exhibits lower pK_a's due to a second, peripheral histidine, which accelerates proton dissociation from the central proton-selective histidine. Amantadine binding to AM2 suppressed proton exchange and imidazole reorientation, indicating that this antiviral drug acts by inhibiting proton shuttling. Solid-state NMR ¹³C-²H distance measurements revealed that amantadine binds the N-terminal pore of the channel near a crucial Ser31, whose mutation to asparagine causes amantadine resistance in circulating influenza A viruses. A second binding site, on the lipid-facing surface of the protein, only occurs when amantadine is in large excess in lipid bilayers. M2 not only functions as a proton channel but also conducts membrane scission during influenza budding in a cholesterol-dependent manner. Solid-state NMR distance experiments revealed that two cholesterol molecules bind asymmetrically to the surface of the tetrameric channel, thus recruiting the protein to the cholesterol-rich budding region of the cell membrane to cause membrane scission.To accelerate full structure determination of viroporins, we developed a suite of ¹⁹F solid-state NMR techniques that measure interatomic distances to 1-2 nm. Using this approach, we determined the atomic structures of influenza BM2, SARS-CoV-2 E, and EmrE, a multidrug-resistance bacterial transporter. pH-induced structural changes of these proteins gave detailed insights into the activation mechanisms of BM2 and E and the proton-coupled substrate transport mechanism of EmrE. The SARS-CoV-2 E protein forms pentameric helical bundles whose structures are distinct between the closed state at neutral pH and the open state at acidic pH. These ¹⁹F-enabled distance NMR experiments are also instrumental for identifying the binding mode and binding site of hexamethylene amiloride in E, paving the way for developing new antiviral drugs that target these pathogenic virus ion channels.

103

项与盐酸金刚烷胺相关的新闻（医药）

2025-03-23

·奇点网

《JAMA·精神病学》：揭示精神疾病的蛋白质密码！科学家发现血液中91种蛋白质的水平与精神分裂症、躁郁症和重度抑郁症等有关

*仅供医学专业人士阅读参考研究精神疾病的生物学机制，因为采样（大脑组织）困难，研究进展并不十分乐观。虽然可以利用外周循环蛋白等便于采样的样本进行研究，但是过去的研究往往通量较低，且容易受到环境因素干扰。全基因组关联研究（GWAS）有助于在大规模样本中发现与精神疾病相关的遗传因素，并深入揭示疾病机制。孟德尔随机化（MR）可以利用基因的随机分配来探索因果关系，避免环境因素的干扰。来自美国范斯坦医学研究所的研究团队，开展了迄今为止最大规模的双样本MR研究，讨论了对神经精神表型存在潜在因果影响蛋白质谱。研究利用英国生物样本库和deCODE Genetics的血液蛋白质组学数据，共鉴定了91种与精神分裂症（SCZ）、双相情感障碍（BD）和重度抑郁症（MDD）和认知任务表现（CTP）高度相关的蛋白质。药物靶向富集分析显示，抗炎药物对于SCZ、金刚烷胺对于BD、视黄酸对于MDD可能具有治疗效果。研究发表在《JAMA·精神病学》杂志上。研究数据来自英国生物样本库药物蛋白质组学项目（UKB-PPP）和deCODE Genetics，分别包括34557名英国个体的2923种蛋白质，以及35559名冰岛个体的4719种蛋白质，对蛋白质通路、蛋白质-蛋白质相互作用（PPI）、基因-药物相互作用、药物靶向性、药物靶点富集等进行分析。使用顺式蛋白质数量性状位点（cis-pQTLs）进行MR分析，鉴定出77种蛋白质可能与精神疾病易感性和CTP存在因果关联，其中SCZ 47种，BD 17种，MDD 7种，CTP 19种。 40%的蛋白质仅依赖单一的遗传变异位点与4种表型形成因果关系，多敏感性分析证实了结果的稳健性。UKB-PPP和deCODE队列使用了不同的蛋白质分析平台（Olink和SomaScan），结果具有中等一致性。使用Trans-pQTL（与蛋白质表达相关的远距离遗传变异）进行MR分析，鉴定出14种可能与精神疾病易感性和CTP存在因果关系的蛋白质，其中SCZ 6种，BD 3种，MDD 1种，CTP 7种。系统回顾发现，除了CTP相关的SYT17蛋白外，其余蛋白质均未被报道过。PI16蛋白在SCZ中表现出广泛的多效性，提示其遗传变异可能通过多条独立的生物途径影响SCZ及其他相关疾病。ITIH4和TWF2蛋白在4种表型中均存在因果关系。 4种表型相关蛋白质汇总许多蛋白质与免疫或炎症功能有关。SCZ的遗传风险与C反应蛋白（CRP）水平降低有关。IL23R是发现的最强的单一信号，水平升高与MDD风险增加和CTP恶化有关。在新发现的精神疾病相关蛋白质中，载脂蛋白B受体表现出与CTP强相关；PCMT1表现出神经保护作用；叶酸水解酶I（FOLH1）与BD风险增加有关。通路富集分析显示，SCZ相关蛋白富集于免疫反应、阿尔茨海默病、帕金森病等神经退行性疾病通路，BD相关蛋白富集于血小板相关肌肽酶介导的蛋白水解通路，MDD相关蛋白富集于神经发育、免疫功能及神经可塑性（MAPK信号通路）相关通路，CTP相关蛋白富集于轴突导向和轴突生成等神经发育和突触功能通路。 SCZ、BD、MDD和CTP相关的蛋白质表达调控位点药物靶点富集分析显示，发现的多种蛋白质已经是现有药物的靶点。SCZ相关蛋白富集于钙通道阻滞剂和烟碱型乙酰胆碱受体（nAChR）靶点，BD相关蛋白与抗精神病药物、情绪稳定剂（如奥氮平、卡马西平、丙戊酸钠）、以及抗NMDA受体药物（金刚烷胺）有关，MDD相关蛋白NEGR1和TYRO3是选择性血清素再摄取抑制剂（如帕罗西汀）和单胺氧化酶抑制剂（如苯乙肼）的靶点，CTP相关蛋白富集于具有促智和抗焦虑作用的药物的靶点。一些已获批药物可能对SCZ、BD和MDD具有治疗效果，比如抗炎药物对于SCZ、金刚烷胺对于BD、视黄酸对于MDD。总的来说，研究共发现了涉及SCZ、BD、MDD和CTP的91种蛋白质，与以往关于外周蛋白质水平或基因表达的研究相比，约一半的关联为首次发现。炎症标志物可能作为早期风险指标，用于预测精神疾病的发生风险。参考文献： Bhattacharyya U, John J, Lam M, et al. Circulating Blood-Based Proteins in Psychopathology and Cognition: A Mendelian Randomization Study. JAMA Psychiatry. Published online March 12, 2025. doi:10.1001/jamapsychiatry.2025.0033 本文作者丨王雪宁

基因疗法信使RNA临床结果临床研究

2025-03-18

·neurolixis.com

18 March 2025 - Neurolixis Publishes Positive Phase 2A Trial Results for NLX-112 in Parkinson’s Disease

Neurolixis today announced the publication of the results from its successful Phase 2A proof-of-concept clinical trial of NLX-112 (befiradol) in Parkinson’s disease. The findings, published in the prestigious journal 𝘔𝘰𝘷𝘦𝘮𝘦𝘯𝘵 𝘋𝘪𝘴𝘰𝘳𝘥𝘦𝘳𝘴, highlight NLX-112’s potential as a first-in-class, non-dopaminergic therapy with dual efficacy in addressing both levodopa-induced dyskinesia (LID) and motor impairment in Parkinson’s patients. The randomized, double-blind, placebo-controlled trial, supported by The Michael J. Fox Foundation and Parkinson’s UK, evaluated NLX-112 in patients with troubling LID. The study successfully met its primary endpoint of safety and tolerability, as well as its secondary endpoint of significantly reducing LID. Notably, NLX-112 also demonstrated anti-parkinsonian effects, significantly improving motor function in study participants. See the full publication (Open Access): 𝗡𝗟𝗫-𝟭𝟭𝟮 𝗿𝗮𝗻𝗱𝗼𝗺𝗶𝘇𝗲𝗱 𝗣𝗵𝟮𝗔 𝘁𝗿𝗶𝗮𝗹: 𝘀𝗮𝗳𝗲𝘁𝘆, 𝘁𝗼𝗹𝗲𝗿𝗮𝗯𝗶𝗹𝗶𝘁𝘆, 𝗮𝗻𝘁𝗶-𝗱𝘆𝘀𝗸𝗶𝗻𝗲𝘁𝗶𝗰 𝗮𝗻𝗱 𝗮𝗻𝘁𝗶-𝗽𝗮𝗿𝗸𝗶𝗻𝘀𝗼𝗻𝗶𝗮𝗻 𝗲𝗳𝗳𝗶𝗰𝗮𝗰𝘆. 𝘔𝘰𝘷𝘦𝘮𝘦𝘯𝘵 𝘋𝘪𝘴𝘰𝘳𝘥𝘦𝘳𝘴, 2025 (https://doi.org/10.1002/mds.30175) 𝗔 𝗡𝗼𝘃𝗲𝗹 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 𝗼𝗳 𝗔𝗰𝘁𝗶𝗼𝗻: Unlike current Parkinson’s treatments that target the dopamine system, NLX-112 acts on the serotonin (5-HT) system, as a highly selective full activator of 5-HT1A receptors. This unique mechanism differentiates NLX-112 from previous serotonergic drugs and is believed to underlie its dual efficacy in reducing dyskinesia and improving motor function. The promising results from this Phase 2A trial support further development of NLX-112 as a transformative therapy for movement disorders. Neurolixis is actively planning next steps in the clinical development program to advance NLX-112 toward potential regulatory approval. 𝗔𝗯𝗼𝘂𝘁 𝗣𝗮𝗿𝗸𝗶𝗻𝘀𝗼𝗻’𝘀 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗮𝗻𝗱 𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗠𝗼𝘃𝗲𝗺𝗲𝗻𝘁 𝗗𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀: Parkinson’s disease is the second most common neurodegenerative disorder, affecting over 10 million people worldwide. Levodopa, the mainstay treatment for Parkinson’s, often leads to debilitating dyskinesias (involuntary movements) after prolonged use. Up to 80% of patients develop LID within ten years of levodopa therapy. Current treatments for LID, such as amantadine, are limited by side effects and variable efficacy, underscoring the need for new therapeutic options. As well as Parkinson’s disease, other disorders also involve dysfunction in the basal ganglia, a brain region critical for coordinating movement. Such disorders include spinocerebellar ataxia, Huntington’s disease, essential tremor and dystonia, and lead symptoms such as tremors, rigidity, and impaired motor control.

临床2期临床结果

2025-02-24

·赞Med

帕金森病疼痛管理：沙非胺的前景与潜力

点击上方“蓝字”关注我们吧！在帕金森病患者中，疼痛问题常常被忽视。甲磺酸沙非胺（既往称沙芬酰胺）是我国最近获批的用于治疗帕金森病的新药，已在改善帕金森病患者的疼痛方面显示出积极结果。一些临床研究报告了接受沙非胺治疗的帕金森病患者的疼痛评分变化，但这些研究尚未被系统总结。因此，一篇发表在《REVUE NEUROLOGIQUE》上的题为“Safinamide for pain management in patients with Parkinson's disease”的系统综述，总结了沙非胺在疼痛管理中的前景与潜力。该研究系统检索了Pubmed、Cochrane Library、Google Scholar 和 Scopus四个数据库，检索文献出版日期截至2023年1月。因纳入的9项随机对照试验未能提供足够的数据进行荟萃分析，研究团队最终进行了定性系统综述。 1.疼痛结局研究发现（表1），每天100 mg剂量的沙非胺在治疗帕金森病疼痛方面比50 mg剂量更有效；此外，与帕金森病其他类型的疼痛相比，沙非胺在减少波动相关疼痛和水肿相关疼痛方面更有效。 2.安全性在几项纳入的研究中，异动症为沙非胺最常见的副作用。在纳入的临床试验中，大约半数的患者存在某种形式的不良事件，然而，出现与沙非胺治疗相关副作用的人数仅占总不良事件人数的一半，且出现严重不良事件在的频率较低，只有一项研究在安慰剂组和S100组中发生了死亡病例，不过这些死亡与沙非胺治疗无关。 3.讨论帕金森病疼痛的性质和潜在机制很复杂，尚未完全了解。据观察，由于黑质致密部（SNc）中多巴胺能神经元的丢失而导致的多巴胺消耗会导致丘脑底核（STN）的去抑制。这种去抑制继而导致谷氨酸能输出神经元的过度刺激，破坏正常的大脑信号处理10。沙非胺的双重作用机制直接解决了基底神经节中的神经递质失衡。沙非胺通过选择性和可逆地抑制单胺氧化酶-B增强左旋多巴的有效性，减少了STN中谷氨酸能神经元的过度激活，并有助于恢复正常的疼痛感知。其非多巴胺能机制通过阻断电压门控钠和钙通道来抑制谷氨酸的释放，从而进一步使过度激活的STN正常化并改善大脑中的疼痛处理。此外，沙非胺的抗谷氨酸活性可以防止谷氨酸兴奋性毒性引起的基底神经节神经组织损伤。保留基底神经节中的神经组织有助于防止疼痛症状恶化11。而且，动物研究表明与金刚烷胺等其他帕金森病药物不同，沙非胺似乎选择性地影响基底神经节回路内的特定区域和通路12。此外，研究提示，波动相关疼痛和水肿引起的疼痛在所有KPPS领域中改善最为显著4、7-8。许多临床试验表明，沙非胺对患者的运动能力和“开”期时间的增加有有益的影响，这可以减轻“关”期的肌张力障碍性疼痛并增加患者的活动，防止外周水肿的形成和后续的疼痛。 4.总结本研究发现，当用作左旋多巴的辅助治疗时，剂量为100mg/天的沙非胺在减轻患者疼痛症状方面显示出巨大的潜力，临床证据表明，沙非胺可能对经历波动相关疼痛和水肿疼痛的患者特别有益，并可减轻总疼痛负担。 Xu等人的研究表明13，截至2021年我国帕金森患者人数已达到508万，与1990年相比，中国帕金森病新发病例数和患者数分别增加了455.7%和678.9%。面对如此庞大的患者基数，改善帕金森病患者的疼痛不仅能够直接减轻患者的痛苦，还能从多方面促进患者的整体健康和生活质量，是帕金森病综合管理中不可或缺的一部分，具有重要的临床意义和社会价值。目前除了止痛药外，新药甲磺酸沙非胺的上市无疑为帕金森病患者的疼痛管理提供了新选择，其前景和潜力已得到多项临床试验及多国长期真实世界数据的支持，期待能为中国帕金森病患者带来更多可能和希望。参考文献 [1] Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord 2014;29:229–37. [2] Cattaneo C, Barone P, Bonizzoni E, Sardina M. Effects of safinamide on pain in fluctuating Parkinson’s disease patients: a post-hoc analysis. JPD 2017;7:95–101. [3] Cattaneo C, Kulisevsky J, Tubazio V, Castellani P. Long-term efficacy of safinamide on Parkinson’s disease chronic pain. Adv Ther 2018;35:515–22. [4] De Masi C, Liguori C, Spanetta M, Fernandes M, Cerroni R, Garasto E, et al. Non-motor symptoms burden in motorfluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study. J Neural Transm 2022;129:1331–8. [5] De Micco R, Satolli S, Siciliano M, De Mase A, Giordano A, Tedeschi G, et al. Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson’s disease patients: a prospective longitudinal study. Neurol Sci 2022;43:357–64. [6] Geroin C, Di Vico IA, Squintani G, Segatti A, Bovi T, Tinazzi M. Effects of safinamide on pain in Parkinson’s disease with motor fluctuations: an exploratory study. J Neural Transm 2020;127:1143–52. [7] Grigoriou S, Martı´nez-Martı´n P, Ray Chaudhuri K, Rukavina K, Leta V, Hausbrand D, et al. Effects of safinamide on pain in patients with fluctuating Parkinson’s disease. Brain and Behavior 2021;11(10):e2336. [8] Santos Garcı´a D, Ya´n˜ ez Ban˜ a R, Labandeira Guerra C, Cimas Hernando MI, Cabo Lo´pez I, Paz Gonza´lez JM, et al. Pain improvement in Parkinson’s disease patients treated with safinamide: results from the SAFINONMOTOR Study. JPM 2021;11:798. [9] Tsuboi Y, Koebis M, Kogo Y, Ishida T, Suzuki I, Nomoto M,et al. Effects of safinamide adjunct therapy on pain in patients with Parkinson’s disease: post hoc analysis of a Japanese phase 2/3 study. J Neurol Sci 2021;429:118070. [10] Lintas A, Silkis IG, Albe´ ri L, Villa AEP. Dopamine deficiency increases synchronized activity in the rat subthalamic nucleus. Brain Res 2012;1434:142–51. [11] Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006;67:S18–23. [12] Pisano` CA, Brugnoli A, Novello S, Caccia C, Keywood C, Melloni E, et al. Safinamide inhibits in vivo glutamate release in a rat model of Parkinson’s disease. Neuropharmacology 2020;167:108006. [13] Xu T, Dong W, Liu J, et al. Disease burden of Parkinson's disease in China and its provinces from 1990 to 2021: findings from the global burden of disease study 2021. Lancet Reg Health West Pac. 2024;46:101078. 提示：本材料仅供医疗卫生专业人士进行医学科学交流，不用于推广目的。

临床研究

100 项与盐酸金刚烷胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00777	盐酸金刚烷胺	N04BB01	DB00915

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
药物引起的锥体外系副作用	美国	Supernus Pharmaceuticals, Inc.	2018-02-16
帕金森障碍	美国	Supernus Pharmaceuticals, Inc.	2017-08-24
甲型流感病毒感染	日本	Sun Pharma Japan Ltd.	1998-11-27
脑梗塞	日本	Sun Pharma Japan Ltd.	1987-10-02
流感病毒感染	中国	国药集团中联药业有限公司	1981-01-01
帕金森病	日本	Sun Pharma Japan Ltd.	1975-04-15

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
行走困难	临床3期	美国	Adamas Pharmaceuticals LLC	2018-03-29
行走困难	临床3期	加拿大	Adamas Pharmaceuticals LLC	2018-03-29
多发性硬化症	临床3期	美国	Adamas Pharmaceuticals LLC	2018-03-29
多发性硬化症	临床3期	加拿大	Adamas Pharmaceuticals LLC	2018-03-29
药物性运动障碍	临床3期	美国	Osmotica Pharmaceutical US LLC	2014-08-18
药物性运动障碍	临床3期	美国	Adamas Pharmaceuticals LLC	2014-08-18
药物性运动障碍	临床3期	加拿大	Adamas Pharmaceuticals LLC	2014-08-18
药物性运动障碍	临床3期	加拿大	Osmotica Pharmaceutical US LLC	2014-08-18
药物性运动障碍	临床3期	法国	Adamas Pharmaceuticals LLC	2014-08-18
药物性运动障碍	临床3期	法国	Osmotica Pharmaceutical US LLC	2014-08-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04387773 (CTgov)	临床4期	帕金森病	8	GOCOVRI	窪鑰窪齋襯範壓淵選構(鏇餘願夢艱簾壓齋艱選) = 製遞遞簾製糧淵積築鏇艱築糧夢鹽蓋淵窪繭網 (糧鬱廠築醖憲選衊襯簾, 6.23) 更多	-	2024-10-10
MDS2023	N/A	帕金森病	53	Responders to amantadine	餘願淵鑰築獵構蓋鹽築(餘憲範襯範艱鹽膚鏇鬱) = 鏇醖餘糧繭構壓餘艱觸築齋獵遞淵觸鏇蓋築淵 (糧鹽鹽網餘齋鬱顧遞壓 )	-	2023-08-27
MDS2023	N/A	帕金森病	53	Nonresponders to amantadine	餘願淵鑰築獵構蓋鹽築(餘憲範襯範艱鹽膚鏇鬱) = 廠襯繭糧觸範築壓憲顧築齋獵遞淵觸鏇蓋築淵 (糧鹽鹽網餘齋鬱顧遞壓 )	-	2023-08-27
NS-Park cohort (MDS2023)	N/A	帕金森病	-	Amantadine	選範艱壓壓願淵選鏇夢(衊夢襯鑰餘艱夢顧範鹹) = 衊築憲淵蓋繭齋製鏇觸艱糧繭製製糧齋鹽醖範 (艱鏇遞鏇憲壓糧鹹遞壓 )	积极	2023-08-27
NCT04952519 (Pubmed \| Respir Med)	临床3期	新型冠状病毒感染	193	Amantadine	網鹽齋遞願膚遞繭糧壓(鹽齋觸襯鹽憲構醖製鹹) = 獵鏇顧鏇醖願遞餘糧糧壓廠遞顧獵願鬱選構製 (簾蓋夢構壓繭廠願齋鑰, 9 ~ 11)	不佳	2023-03-15
NCT04952519 (Pubmed \| Respir Med)	临床3期	新型冠状病毒感染	193	Placebo	網鹽齋遞願膚遞繭糧壓(鹽齋觸襯鹽憲構醖製鹹) = 鏇醖鑰廠淵齋構築夢鏇壓廠遞顧獵願鬱選構製 (簾蓋夢構壓繭廠願齋鑰, 8 ~ 11)	不佳	2023-03-15
MDS2022	临床3期	运动失调	-	AMT DR/ER	獵鹽築蓋淵鬱鑰觸醖獵(膚憲齋壓鹽選簾鹽鹹蓋) = 獵觸構衊淵顧蓋選壓簾製簾膚齋獵簾窪餘窪鹽 (築網遞襯鏇衊築獵襯鹽 ) 更多	-	2022-09-15
MDS2022	临床3期	运动失调	-	Placebo	獵鹽築蓋淵鬱鑰觸醖獵(膚憲齋壓鹽選簾鹽鹹蓋) = 製艱蓋壓願鹹廠築獵鹹製簾膚齋獵簾窪餘窪鹽 (築網遞襯鏇衊築獵襯鹽 ) 更多	-	2022-09-15
EAN2022	N/A	新型冠状病毒感染 \| 帕金森病	-	Amantadine	願膚選鏇築選襯觸窪遞(糧積憲構範糧鹽膚憲淵) = 鹽淵構獵製鹹壓醖積簾網餘網簾積蓋餘壓廠鬱 (鏇蓋壓鬱網夢願艱壓壓, 3)	-	2022-06-24
NCT04273737 (CTgov)	临床4期	认知功能障碍 \| 脑瘫	11	Amantadine Hydrochloride	築衊壓餘壓選製網艱齋(壓積憲鹽願齋襯壓膚獵) = 鑰獵窪壓遞鬱鏇觸顧醖淵獵獵網夢餘襯齋願觸 (鹹餘襯範遞製鹽顧蓋醖, 8.050) 更多	-	2022-05-31
P16-9.007 (AAN2022)	N/A	小脑疾病	12	Amantadine	積觸網鬱鑰製鬱憲築夢(簾獵鹹膚繭鑰夢鏇廠製) = Constipation was the most common side effect 願觸壓獵簾範網憲製鏇 (獵願膚範襯壓艱築鹹積 )	积极	2022-05-03
NCT03567057 (CTgov)	临床3期	多发性硬化症 \| 行走困难	424	Placebo+ADS-5102 (Placebo/274 mg ADS-5102)	鹹顧選淵選廠網網壓壓 = 齋憲齋蓋築製醖醖選夢窪衊膚憲餘廠糧範膚繭 (廠鬱壓簾構繭衊選觸襯, 網壓鹹獵憲鬱夢遞鬱鏇 ~ 廠製選糧鬱膚觸築艱醖) 更多	-	2022-01-18
NCT03567057 (CTgov)	临床3期	多发性硬化症 \| 行走困难	424	ADS-5102 (137 mg ADS-5102/274 mg ADS-5102)	鹹顧選淵選廠網網壓壓 = 齋窪壓餘糧衊鹹構廠鹽窪衊膚憲餘廠糧範膚繭 (廠鬱壓簾構繭衊選觸襯, 願壓範遞觸餘願艱顧淵 ~ 憲蓋齋鬱鏇廠製願觸簾) 更多	-	2022-01-18
NCT03436199 (CTgov)	临床3期	多发性硬化症 \| 行走困难	558	Placebo	夢醖襯簾鏇襯繭鏇壓遞 = 構積廠艱糧範憲夢膚夢醖廠衊鏇艱夢鏇膚遞蓋 (觸簾繭衊構衊艱憲鹽艱, 蓋膚鹽願衊鬱憲鹽淵淵 ~ 夢憲獵觸齋艱積網範餘) 更多	-	2021-12-21